biostudies-literatureUhlik MNCI NIH HHS1158345https://www.ebi.ac.uk/biostudies/studies/S-EPMC10213262biostudies-literatureUnknown13<h4>Introduction</h4>Most predictive biomarkers approved for clinical use measure single analytes such as genetic alteration or protein overexpression. We developed and validated a novel biomarker with the aim of achieving broad clinical utility. The Xerna™ TME Panel is a pan-tumor, RNA expression-based classifier, designed to predict response to multiple tumor microenvironment (TME)-targeted therapies, including immunotherapies and anti-angiogenic agents.<h4>Methods</h4>The Panel algorithm is an artificial neural network (ANN) trained with an input signature of 124 genes that was optimized across various solid tumors. From the 298-patient training data, the model learned to discriminate four TME subtypes: Angiogenic (A), Immune Active (IA), Immune Desert (ID), and Immune Suppressed (IS). Frontiers in oncologyXerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers.PMC10213262R01 CA263575Liu HBenjamin LKrieg AMPointing DCvitkovic RUhlik MCulm KSantos VCLee JStajdohar MZganec MAusec LMalafa MIyer SRosengarten RPytowski BfalseXerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers.<h4>Introduction</h4>Most predictive biomarkers approved for clinical use measure single analytes such as genetic alteration or protein overexpression. We developed and validated a novel biomarker with the aim of achieving broad clinical utility. The Xerna™ TME Panel is a pan-tumor, RNA expression-based classifier, designed to predict response to multiple tumor microenvironment (TME)-targeted therapies, including immunotherapies and anti-angiogenic agents.<h4>Methods</h4>The Panel algorithm is an artificial neural network (ANN) trained with an input signature of 124 genes that was optimized across various solid tumors. From the 298-patient training data, the model learned to discriminate four TME subtypes: Angiogenic (A), Immune Active (IA), Immune Desert (ID), and Immune Suppressed (IS). 2023-01-01T00:00:00Z20232026-05-29T02:21:33.669Z2025-02-19T02:23:55.316ZS-EPMC102132623725194910.3389/fonc.2023.1158345